STRIDES VIVIMED PTE LTD (FORMERLY VIVIMED GLOBAL GENERICS PTE LTD) BALANCE SHEET AS AT MARCH 31, 2018

	DALANCE SHEET AS AT MARCH 51, 2010		
			Amount in USD
			31-Mar-18
Α	ASSETS		
ı	Non-current assets		
	(a) Other intangible assets	1	2,681,886
	(b) Intangibles assets under development	-	100,000
	Total non-current assets		2,781,886
II	Current assets		
	(a) Financial assets		
	(i) Trade receivables	2	4,800
	(ii) Cash and cash equivalents	3	80,502
	Total current assets	•	85,302
	TOTAL ASSETS	-	2,867,187
		=	
В	EQUITY AND LIABILITIES		
	Equity		
-	(a) Equity share capital		-
	(b) Other equity	4	2,614,900
	Total Equity		2,614,900
П	Liabilities		
1	Current liabilities		
	(a) Financial liabilities	_	
	(i) Trade payables	5	2,288
	(ii) Other financial liabilities Total current liabilities	6	250,000
	Total current liabilities		252,288
	TOTAL EQUITY AND LIABILITIES		2,867,187

STRIDES VIVIMED PTE LTD

(FORMERLY VIVIMED GLOBAL GENERICS PTE LTD) STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2018

Amount in USD

	Particulars	Note No.	31-Mar-18
1	Revenue from operations	_	-
2	Other Income	7.	186
3	Total Revenue (1+2)		186
4	Expenses		
-	(a) Finance costs	8	1,033
	(b) Depreciation and amortisation expense	1	165,375
	(c) Other expenses	9	66,392
	Total expenses		232,799
5	Profit / (Loss) before exceptional items and taxes (3-4)		(232,613)
6	Exceptional Item		-
7	Profit / (Loss) before taxes (5+6)		(232,613)
8	Tax Expense:		
	(1) Current tax		-
	(2) Deferred tax	-	-
	Total tax expenses		-
VII	Profit / (Loss) for the year after tax		(232,613)

STRIDES VIVIMED PTE LTD (FORMERLY VIVIMED GLOBAL GENERICS PTE LTD) STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2018

(A) Equity share capital

Particulars	Amount in USD
Balance as at March 31, 2017	-
Changes in equity share capital during the year	-
Balance as at March 31,2018	-

(B) Other equity Amount in USD

Caner equity				7 000
		Reserves and	Items of other	
	Money	Surplus	comprehensive income	
Particulars	Pending		Re -measurement of the	Total
	Allotment		defined benefit liabilities /	
		Retained earnings	(assets)	
Balance as at March 31, 2017	=	-	-	=
Add: Money received from shareholder	2,847,513			2,847,513
Profit/loss for the year	-	(232,613)	-	(232,613)
Other comprehensive income for the year (net of tax)	-		-	-
Total comprehensive income	2,847,513	(232,613)	-	2,614,900
Balance as at March 31,2018	2,847,513	(232,613)	-	2,614,900

STRIDES VIVIMED PTE LTD Notes forming part of financial statement

Note 1 Intangible assets

Amount in USD

		Gross block		Accumulated	amortisations	Net block
Particulars	Additions	Deletions	As at March 31, 2018	Amortisation expense for the vear	As at March 31, 2018	As at March 31, 2018
Registrations & brands	2,847,261	ı	2,847,261	165,375	165,375	2,681,886
Total	2,847,261	-	2,847,261	165,375	165,375	2,681,886

STRIDES VIVIMED PTE LTD (FORMERLY VIVIMED GLOBAL GENERICS PTE LTD) Notes forming part of financial statement

No.

Trade receivables	Amount in USD
Particulars	31-Mar-18
Unsecured	
Considered good	4,800
Considered doubtful	-
	4,800
Less: Allowance for doubtful trade receivables	-
Total	4,800

3	Cash and cash equivalents	Amount in USD
	Particulars	31-Mar-18
	Balances with banks:	
	In current accounts	80,502
	Total	80,502

Amount in USD
31-Mar-18
2,847,513
2,847,513
-
(232,613)
(232,613)
2,614,900

5	Trade payables	Amount in USD
	Particulars	31-Mar-18
	Trade payable	2,288
	Total	2,288

6	Other financial liabilities	Amount in USD
	Particulars	31-Mar-18
	Payable to group entities	250,000
	Total	250,000

STRIDES VIVIMED PTE LTD (FORMERLY VIVIMED GLOBAL GENERICS PTE LTD) Notes forming part of financial statement

Note

No.

7	Other Income	Amount in USD
	Particulars	31-Mar-18
	Interest Income	186
	Total	106

8	Finance cost	Amount in USD
	Particulars	31-Mar-18
	Bank charges and commission	1,033
	Total	1,033

Other expenses	Amount in USD
Particulars	31-Mar-18
Research and development expenses	48,124
Net loss on foreign currency transactions	2
Professional fees	15,980
Payment to Auditors - For Statutory Audit	2,286
Total	66,392